TGFB1 and neoplasm: We hypothesized that αPDL1 can be used not only to target nanoparticles with TGF-β1 siRNA to given cells, converting the immune-excluded phenotype to the inflamed phenotype, but also to convey immune checkpoint blockade, further reversing T cell exhaustion and enhancing the anti-tumor effect of ICB therapy.